Compare YMAT & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMAT | BOLT |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | Taiwan | United States |
| Employees | 65 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.3M |
| IPO Year | N/A | 2021 |
| Metric | YMAT | BOLT |
|---|---|---|
| Price | $1.69 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 450.5K | 16.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.24 | $3.75 |
| 52 Week High | $6.45 | $7.20 |
| Indicator | YMAT | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 47.89 |
| Support Level | $0.33 | $3.90 |
| Resistance Level | $2.47 | $4.46 |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 55.24 | 38.89 |
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.